ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2025
Hypoxia-Induced circPRELID2 Promotes Gastric Cancer Metastasis by Facilitating ZEB2 Translation via PCBP1 O-GlcNAcylation.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- UDP-Glucose-6-Dehydrogenase Mediated O-GlcNAcylation of Tight Junction Protein 1 Suppresses Metastasis in Renal Cell Carcinoma.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- RNA‑binding proteins as epithelial transcriptome orchestrators in gastric cancer: Immune‑metabolic crosstalk and therapeutic vulnerability (Review).International journal of molecular medicine · 2026Review
- Gut microbiota pathways linking primary sclerosing cholangitis to colorectal cancer: theFrontiers in microbiology · 2026Article
- Protein O-GlcNAcylation in Health and Diseases.MedComm · 2025Review
- Hypoxia-Induced circPRELID2 Promotes Gastric Cancer Metastasis by Facilitating ZEB2 Translation via PCBP1 O-GlcNAcylation.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Circular RNAs (circRNAs) are involved in the occurrence and development of various carcinomas. However, the biogenesis, function and underlying mechanism of hypoxia-induced circRNA in gastric cancer (GC) are poorly understood. Here, a novel circRNA, circPRELID2, which is upregulated by HIF1A under hypoxic conditions, is identified. circPRELID2 is highly expressed in GC tissues, and positively correlates with lymph node invasion, vascular invasion in GC patients. Elevated circPRELID2 promotes the epithelial-mesenchymal transition (EMT) and metastasis of GC cells both in vitro and in vivo under hypoxic conditions. Mechanistically, HIF1A directly binds to the PRELID2 promoter to transcriptionally increase the expression of PRELID2 pre-mRNA in response to hypoxia. Moreover, protein kinase DYRK1A mediates SFPQ phosphorylation to promote the interaction between SFPQ and SAM68, further forming a DYRK1A-SFPQ-SAM68 ternary complex. Subsequently, the DYRK1A-SFPQ-SAM68 complex binds to Alu-containing introns flanking the circPRELID2-forming exons in the PRELID2 pre-mRNA to promote circPRELID2 circularization. Furthermore, circPRELID2 interacts with PCBP1 and promotes the cytoplasmic retention of PCBP1. CircPRELID2 enhances OGT-mediated PCBP1 O-GlcNAcylation at Threonine 99 site in the cytoplasm, which disrupts the binding of PCBP1 to the 3'-UTR of ZEB2, resulting in the reversal of ZEB2 translation silencing, and ultimately promoting the EMT and metastasis of GC cells. These findings reveal a new regulatory mechanism of circRNA biogenesis, and also uncover that circPRELID2 participates in the translation of ZEB2 during GC metastasis via the modulation of PCBP1 O-GlcNAcylation, which provides a promising prognostic biomarker and therapeutic target for GC metastasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.